How Big Pharmai Is Redefining the Backbone of Decentralized Science

Big Pharmai is starting a project to adopt decentralized science (DeSci) to change the secretive and monopolized pharmaceutical industry. This effort focuses on breaking down barriers large pharmaceutical companies create and promote collaboration, transparency, and new research methods. 

Led by well-known biohacker Anthony Fauccai, the movement draws from grassroots biohacking experiences and emphasizes the idea that people should take back control of drug development from big corporations. The project is committed to fixing the pharmaceutical industry by making drug research and development accessible and fair for everyone. 

Significance and Concept of Big Pharmai

Big Pharmai's adoption of decentralized science (DeSci) seeks to change drug development by endorsing significant projects and expediting innovation. By supporting the most impactful DeSci projects, this initiative aims to accelerate innovation and significantly change the pharmaceutical industry.

The initiative focuses on backing high-potential DeSci projects to foster a collective effort that maximizes the potential for a civilization-scale transformation in healthcare. Empowering individuals and smaller organizations seeks to democratize drug development, ensuring that new treatments and medical breakthroughs are accessible to all.

Mechanism and Architecture

Big Pharmai supports decentralized science (DeSci) through several key mechanisms. 

First, they utilize decentralized autonomous organizations (DAOs) to allow community stakeholders, including researchers and patients, to participate in project funding and direction decision-making. They also pool resources from various stakeholders to fund innovative research, ensuring adequate financial backing for impactful DeSci projects. Additionally, the initiative promotes biohacking by encouraging small-scale experiments and open-source collaboration.

Partnerships and Collaborations

In recent years, Big Pharmai has fostered connections with numerous biotech startups, ensuring the integration of AI technologies in drug development and increasing innovation. However, the pharmaceutical industry faces rising R&D costs, and drug development takes 12–18 years, costs $2 to 3 billion, and only about 10% of candidates successfully gain regulatory approval. 

AI has the potential to revolutionize drug discovery by accelerating the R&D process, reducing costs, and increasing the chances of approval. Since 2015, over 100 AI partnerships between Big Pharmai and AI vendors have been established, with a 575% increase in such partnerships by 2020, according to GlobalData.

Summary

Big Pharmai's new approach to decentralized science represents a change in the pharmaceutical industry, focused on teamwork, transparency, and making healthcare more accessible. This initiative, led by Anthony Fauccai, seeks to overcome the barriers created by traditional pharmaceutical methods, encouraging innovation and better health outcomes.

Project Overview

• Project Name: Big Pharmai
• Project Website: bigpharm.ai
• Total supply: 1,099,999,983
• Explorer: Solscan
• Contract: CX9YDTED9TWgVXVoFy8JL9gSSAEWcTv4mzjLSv17LQsj
• Telegram: big_pharmai_portal
• X: twitter.com/Big_Pharmai